UNSPSC 51342603: Fomivirsen sodium

This classification denotes an antisense agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z6W3S36X5. European Medicines Agency schedules Fomivirsen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02253MIG. Fomivirsen sodium generally arises in the molecular formula C204H243N63O114P20S20.20NA. The term 'fomivirsen sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule fomivirsen sodium under HS 29349990 and SITC 51579.

Fomivirsen sodium bears US NLM identifiers UMLS ID C0982166 and NCI Concept Code C61770. SMILES: As of Q4 2014, FOMIVIRSEN SODIUM remains US FDA's Preferred Term for this commodity.

UNSPSC 51342603 Fomivirsen sodium is a Commodity code for a specific antiviral pharmaceutical product; however, the recent state and local opportunities posted under this code do not align with fomivirsen sodium procurement. Instead, the tagged opportunities reflect broader pharmaceutical and medical supply acquisition — including antibiotic tablets, naloxone, and drug deactivation systems — suggesting either tagging inconsistency or use of the code as a catch-all for pharmaceutical warehouse and emergency-response medical goods. State and local buyers use this code family to source pharmaceutical products and medical supplies through piggyback agreements, cooperative purchasing consortia, and competitive bidding processes. Issuing bodies include state health departments and county public-health and community-health authorities. The work involves establishing standing contracts for pharmaceutical inventory and emergency-response medical equipment with quarterly or scheduled delivery cycles, fixed-fee pricing, and multi-year terms with renewal options.

Activity appears concentrated in Florida and Illinois, with the Illinois Department of Public Health executing a $2,999,999.11 piggyback pharmaceutical warehouse award through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic tablets over 12 months plus renewal years, and Seminole County, Florida issuing an IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the county community health building (response deadline July 26, 2023, now closed). Buyers across this code require E-Verify compliance, drug-free workplace certification, and standard commercial insurance; some procurements carry FEMA funding and associated federal compliance obligations including Clean Air Act and water-pollution-control adherence.